This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Thrombolysis  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The OASIS-6 trial¹ was not the first to demonstrate that a 7-day (or hospitalization duration) treatment with an anticoagulant is superior to a 48-hour infusion of UFH therapy. Both the Assessment of the Safety and Efficacy of New Thrombolytic Regimen 3 (ASSENT-3) trial² and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Events (ESSENCE) trial³ have shown similar findings. A trial of anticoagulant with an equal duration of UFH did not display this difference.⁴ The differences in treatment duration in OASIS-6 may have affected the development of deep vein thrombosis (DVT) and pulmonary embolism.

Within the past 2 decades, the treatment for acute myocardial infarction has become more complex, and the risk of DVT appears to have been only partially incorporated into newer treatment regimens. In OASIS-6, baseline data suggest that many patients were at higher risk for DVT occurrence (such as those with congestive heart failure), . . . [Full Text of this Article]

Michael J. Peeters, PharmD
michael.peeters@utoledo.edu
University of Toledo College of Pharmacy
Toledo, Ohio

Borys Sydoruk, BScPharm
Calgary, Alberta

RELATED LETTERS

Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction
Frank Hartig, Philipp Eller, and Christoph Pechlaner
JAMA. 2006;296(17):2087.
EXTRACT | FULL TEXT  

Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction
Neeraj Bhala, Praveen Rajasekhar, and Iain Moore
JAMA. 2006;296(17):2087-2088.
EXTRACT | FULL TEXT  

Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction—Reply
Salim Yusuf and Shamir R. Mehta
JAMA. 2006;296(17):2088-2089.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Fondaparinux in ST-Segment Elevation Myocardial Infarction: The Drug, the Strategy, the Environment, or All of the Above?
Robert M. Califf
JAMA. 2006;295(13):1579-1580.
EXTRACT | FULL TEXT  

Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial
The OASIS-6 Trial Group*
JAMA. 2006;295(13):1519-1530.
ABSTRACT | FULL TEXT  

The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials
David Moher, Kenneth F. Schulz, Douglas Altman, and for the CONSORT Group
JAMA. 2001;285(15):1987-1991.
ABSTRACT | FULL TEXT